Meeting
2017 Genitourinary Cancers Symposium
The SUNPAZ study: Results of an open label, single arm trial to evaluate patients with mRCC treated with everolimus after failure of first line therapy with sunitinib or pazopanib.
Authors
Martin Schostak
University Hospital Magdeburg, Magdeburg, Germany
Martin Schostak , Arnd Nusch , Patrick de Geeter , Thomas Decker , Anna Resch , Claudia Weiss , Stephan H. Schmitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01514448
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 473)
DOI
10.1200/JCO.2017.35.6_suppl.473
Abstract #
473
Poster Bd #
E12
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.
First Author: Martin Boegemann
Poster
2018 Genitourinary Cancers Symposium
Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).
First Author: Paul L. de Souza
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.
First Author: Thomas Cosgriff
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-word evidence in patients treated with pazopanib for advanced/metastatic renal cell carcinoma (mRCC): The APOLON study.
First Author: Antoine Thiery-Vuillemin